Sana Biotechnology (NASDAQ: SANA) — Perfil da empresa, notícias e dados financeiros
Sana Biotechnology develops engineered cell therapies across various medical areas, striving to innovate patient-centric treatments.
Sana Biotechnology
Sana Biotechnology (NASDAQ:SANA) focuses on creating and delivering engineered cells as medicines for patients. They're deeply invested in developing therapies that touch on a wide range of medical areas, including oncology, diabetes, central nervous system disorders, and cardiovascular diseases. Their projects harness cutting-edge technology to modify the fundamental building blocks of life with the aim to treat, and potentially cure, debilitating medical conditions. With an innovative spirit at its core, Sana is dedicated to pushing the boundaries of medicine, striving to bring transformative and accessible treatments to people around the world. Their objectives are clear: innovate in the medical field, ensure treatments are patient-centric, and achieve lasting solutions to complex diseases.
Resumo
Operações
Produtos e/ou serviços de Sana Biotechnology
- In Vivo Cell Engineering platform aiming to repair and control genes in patients' cells for a wide range of diseases.
- Ex Vivo Gene Correction technologies focused on editing cells outside the body then transplanting them back to treat genetic disorders.
- CAR-T therapy development for cancer treatment, leveraging innovative cell engineering to enhance efficacy and safety.
- Hypoimmune Platform designed to create universally compatible cells resistant to immune rejection, advancing organ transplantation and cell therapies.
- Manufacturing and scale-up processes for producing high-quality, scalable cell and gene therapy products efficiently.
equipe executiva do Sana Biotechnology
- Steven D. HarrPresident, CEO & Director
- Brian D. PiperExecutive VP & CFO
- Susan WyrickTreasurer, Principal Accounting Officer and Senior VP of Finance & Accounting
- Snehal PatelExecutive VP & Chief Technical Officer
- Dhavalkumar D. PatelExecutive VP & Chief Scientific Officer
- Aaron M. GrossmanExecutive VP, Chief Legal Officer & Corporate Secretary
- Debra WisdomVP & Head of People
- Gary MeiningerExecutive VP & Chief Medical Officer
- Yuko SoneokaSVP & Head of Intellectual Property
- John GerecitanoSenior Vice President, Clinical Lead, Hematology & Oncology Development
Principais indicadores financeiros
Resultados divulgados pela Sana Biotechnology, em USD.
- Cap. de mercado
- 739,4 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.8
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -191 mi | -244,2 mi | |
| 0 | -272,7 mi | -266,8 mi | |
| 0 | -293,1 mi | -283,3 mi | |
| 0 | -272,6 mi | -266,4 mi |